Endothelial progenitor cells dysfunction and senescence: Contribution to oxidative stress

Current Cardiology Reviews

Volumn 4, Issue 4, 2008, Pages 275-286

  Imanishi, Toshio ^a   Tsujioka, Hiroto ^a   Akasaka, Takashi ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Angiotensin II; Endothelial progenitor cell; Nitric oxide; Oxidative stress; Senescence; Telomerase

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN II; ATORVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTRADIOL; ESTROGEN DERIVATIVE; GROWTH FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; RAMIPRIL; REACTIVE OXYGEN METABOLITE; TELOMERASE; VALSARTAN;

ACUTE HEART INFARCTION; ANGIOGENESIS; APOPTOSIS; CARDIOVASCULAR DISEASE; CELL ACTIVITY; CELL ADHESION; CELL AGING; CELL DAMAGE; CELL DIFFERENTIATION; CELL FUNCTION; CELL KINETICS; CELL METABOLISM; CELL MOTILITY; CELL PROLIFERATION; CELL PROTECTION; CELL STIMULATION; CELL STRESS; CELL SURVIVAL; CLINICAL TRIAL; CONCENTRATION RESPONSE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DISEASE COURSE; DNA DAMAGE; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HEMATOPOIETIC STEM CELL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SENESCENCE; SHEAR STRESS; STEM CELL; TELOMERE; TISSUE REGENERATION; TISSUE REPAIR;

EID: 65649116946     PISSN: 1573403X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340308786349435     Document Type: Review

References (156)

1. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-967.
2. Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest 2000; 105: 71-77.
3. Vasa M, Fichtlscherer S, Aisher A, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001; 89: e1-e7.
4. Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348: 593-600.
5. Tepper OM, Galiano RD, Capla JM, et al. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 2002; 106: 2781-2786.
6. Vasa M, Fichtlscherer S, Adler K, et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 2001; 103: 2885-2890.
7. Scheubel RJ, Zorn H, Silber RE, et al. Age-dependent depression in circulating endothelial progenitor cells in patients undergoing coronary artery bypass grafting. J Am Coll Cardiol 2003; 42: 2073-2080.
8. Wassmann S, Wassmann K, Nickenig G. Modulation of oxidant and antioxidant enzyme expression and function in vascular cells. Hypertension 2004; 44: 381-386.
9. Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature: Molecular and cellular mechanism. Hypertension 2003; 42: 1075-1081.
10. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress. Circ Res 2000; 87: 840-844.
11. Touyz RM. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: What is the clinical significance? Hypertension 2004; 44: 248-252.
12. Ogita H, Liao J. Endothelial function and oxidative stress. Endothelium 2004; 44: 248-252.
13. Blokhina O, Virolainen E, Fagerstedt KY. Antioxidants, oxidative damage and oxygen deprivation stress: a review. Ann Bot (Lond) 2003; 91: 179-194.
14. Dernbach E, Urbich C, Brandes RP, et al. Antioxidative stress-associated genes in circulating progenitor cells: Evidence for enhanced resistance against oxidative stress. Blood 2004; 104: 3591-3597.
15. He T, Peterson TE, Holmuhamedov EL, et al. Human endothelial progenitor cells tolerate oxidative stress due to intrinsically high expression of manganese superoxide dismutase. Arterioscler Thromb Vasc Biol 2004; 24: 2021-2027.
16. Dernbach E, Urbich C, Brandes RP, Hofmann WK, Zeiher AM, Dimmeler S. Antioxidative stress-associated genes in circulating progenitor cells: evidence for enhanced resistance against oxidative stress. Blood 2004; 104: 3591-3597.
17. Ingram DA, Krier TR, Mead LE, et al. Clonogenic endothelial progenitor cells are sensitive to oxidative stress. Stem Cells 2007; 25: 297-304.
18. Hur J, Yoon CH, Kim HS, et al. Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler Thromb Vasc Biol 2004; 24: 288-293.
19. Gulati R, Jevremovic D, Peterson TE, et al. Autologous culture-modified mononuclear cells confer vascular protection after arterial injury. Circulation 2003; 108: 1520-1526.
20. Shi Q, Raffi S, Wu MH, et al. Evidence for circulating bone marrow-derived endothelial cells. Blood 1998; 92: 362-367.
21. Gulati R, Jevremovic D, Peterson TE, et al. Diverse origin and function of cells with endothelial phenotype obtained from adult human blood. Circ Res 2003; 93: 1023-1025.
22. Zhang ZG, Zhang L, Jiang Q, Chopp M. Bone marrow-derived endothelial progenitor cells participate in cerebral neovascularization after focal cerebral ischemia in the adult mouse. Circ Res 2002; 90: 284-288.
23. Civin CI, Banquerigo ML, Strass LC, Loken MR. Antigenic analysis of hematopoiesis. VI. Flow cytometric characterization of My-10 positive progenitor cells in normal human bone marrow. Exp Hematol 1987; 15: 10-17.
24. Fina L, Molgaard HV, Robertson D, et al. Expression of the CD34 gene in vascular endothelial cells. Blood 1990; 75: 2417-2426.
25. Dong C, Crawford L, Goldschmidt-Clermont PJ. Endothelial progenitor obsolescence and atherosclerotic inflammation. J Am Coll Cardiol 2005; 45: 1458-1460.
26. Peichev M, Naiyer AJ, Pereira D, et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000; 95: 952-958.
27. Yin AH, Miraglia S, Zanjani ED, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997; 90: 5002-5012.
28. Miraglia S, Godfrey W, Yin AH, et al. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 1997; 90: 5013-5021.
29. Friedrich EB, Walenta K, Scharlau J, Nickenig G, Werner N. CD34-/CD133+/ VEGFR-2+ endothelial progenitor cell subpopulation with potent vasoregenerative capacities. Circ Res 2006; 98: e20-e25.
30. Romagnani P, Annunziato F, Liotta F, et al. CD14+CD34low cells with stem cell phenotypic and functional features are the major source of circulating endothelial progenitors. Circ Res 2005; 97: 314-322.
31. Elsheikh E, Uzunel M, He Zhong, Holgersson J, Nowak G, Sumitran-Holgersson S. Only a specific subset of human peripheral-blood monocytes has endothelial-like functional capacity. Blood 2005; 106: 2347-2355.
32. Rehman J, Li J, Orschell CM, March KL. Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 2003; 107: 1164-1169.
33. Gulati R, Jevrempovic D, Peterson TE, et al. Diverse origin and function of cells with endothelial phenotype obtained from adult human blood. Circ Res 2003; 93: 1023-1025.
34. Rockmaaker MB, Vergeer M, van Zonneveld Aj, Rabelink TJ, Verhaar MC. Endothelial progenitor cells: mainly derived from the monocyte/ macrophage containing CD34- but also partly derived from the hematopoetic stem cell containing CD34+ mononuclear population. Circulation 2003; 108: 150e.
35. Ingram DA, Mead LE, Tanaka H, et al. Identification of a novel hierarchy of endothelial progenitor cells utilizing human peripheral and umbilical cord blood. Blood 2004; 104: 2752-2760.
36. Urbich C, Heeschen C, Aisher A, Dernbach E, Zeiher AM, Dimmeler S. Relevance of monocytic features for neovascularization capacity of circulating endothelial progenitor cells. Circulation 2003; 108: 2511-2516.
37. Kalka C, Matsuda H, Takahashi T, et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci USA 2000; 97: 3422-3427.
38. Urbich C, Dimmeler S. Endothelial progenitor cells: functional characterization. Trends Cardiovasc Med 2004; 14: 318-322.
39. Hur J, Yang HM, Yoon CH, et al. Identification of a novel role of T cells in postnatal vasculogenesis: characteristics of endothelial progenitor cell colonies. Circulation 2007; 116: 1671-1682.
40. Heissig B, Hattori K, Dias S, et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 2002; 109: 625-637.
41. Hristov M, Weber C. Endothelial progenitor cells: characterization, pathophysiology, and possible clinical relevance. J Cell Mol Med 2004; 8: 498-508.
42. Byrne A, Bouchier-Hayes DJ, Harmey JH. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med 2005; 9: 777-794.
43. Kucia M, Jankowski K, Reca R, et al. CXCR4-SDF-1 signaling, locomotion, chemotaxis and adhesion. J Mol Histol 2004; 35: 233-245.
44. Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 2004; 95: 343-353.
45. Lataillade JJ, Clay D, Dupuy C, et al. Chemokine SDF-1 enhances circulating CD34(+) cell proliferation in synergy with cytokines: possible role in progenitor survival. Blood 2000; 95: 756-768.
46. Ceradini DJ, Kulkarni AR, Callaghan MJ, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004; 10: 858-864.
47. Schober A, Karshovska E, Zernecke A, Weber C. SDF-1α-mediated tissue repair by stem cells: a promising tool in cardiovascular medicine? Trends Cardiovasc Med 2006; 16: 103-108.
48. Massberg S, Konrad I, Schurzinger K, et al. Platelets secrete stromal cell-derived factor 1alpha and recruit bone marrow-derived progenitor cells to artrial thrombi in vivo. J Exp Med 2006; 203: 1221-1233.
49. Hristov M, Zernecke A, Bidzhekov K, et al. Importance of CXC chemokine receptor 2 in the homing of human peripheral blood endothelial progenitor cells to sites of arterial injury. Circ Res 2007; 100: 590-597.
50. Zernecke A, Schober A, Bot I, et al. SDF-1α/CXCR4 axis is instumental in neointimal hyperplasia and recruitment of smooth muscle progenitor cells. Circ Res 2005; 96: 784-791.
51. Walter DH, Haendeler J, Reinhold J, et al. Impaired CXCR4 signaling contributes to the reduced neovascularization capacity of endothelial progenitor cells from patients with coronary artery disease. Circ Res 2005; 97: 1142-1151.
52. Cho HJ, Kim HS, Lee M, et al. Mobilized endothelial progenitor cells by granulocyte-macrophage colony-stimulating factor accelerate reendotheliazation and reduce vascular inflammation after intravascular radiation. Circulation 2003; 108: 2918-2925.
53. Ben-Porath I, Weinberg RA. When cells get stressed: An integrative view of cellular senescence. J Clin Invest 2004; 113: 8-13.
54. Wright WE, Shay JW. Histological claims and current interpretations of replicative aging. Nat Biotechnol 2002; 20: 682-688.
55. Sherr CJ, DePinho RA. Cellular senescence: Mitotic clock or culture shock? Cell 2000; 102: 407-410.
56. Campisi J. Cancer, aging and cellular senescence. In Vivo. 2000; 14: 2495-2502.
57. Sitte N, Merker K, Von Zglinicki T, Grune T, Davies KJ. Protein oxidation and degradation during cellular senescence of human BJ fibroblasts. I. Effects of proliferative senescence. FASEB J 2000; 14: 2495-2502.
58. Narita M, Nunez S, Heard E, et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 2003; 113: 703-716.
59. Chen J, Goligorsky MS. Premature senescence of endothelial cells: Methusaleh's dilemma. Am J Physiol Heart Circ Physiol 2006; 290: 1729-1739.
60. Serrano M, Blasco MA. Putting the stress on senescence. Curr Opin Cell Biol 2001; 13: 748-753.
61. Faragher RG, Kipling D. How might replicative senescence contribute to human agening? Bioassays 1998; 20: 985-991.
62. Gire Roux P, Wynford-Thomas D, Brondello JM, Dulic V. DNA damage checkpoint kinase Chk2 triggers replicative senescence. EMBO J 2004; 23: 2554-2563.
63. Kaneko T, Tahara S, Taguchi T, Kondo H. Accumulation of oxidative DNA damage, 8-oxo-2′-deoxyguanoside, and change of repair systems during in vitro cellular aging of cultured human skin fibroblasts. Mutat Res 2001; 487: 19-30.
64. Chen Q, Ames BN. Senescence-like growth arrest induced by hydrogen peroxide in human diploid fibroblast F65 cells. Proc Natl Acad Sci USA 1994; 91: 4130-4134.
65. Robles SJ, Adami GR. Agents that cause DNA double strand breaks lead to p16INK4a enrichment and the premature senescence of normal fibroblasts. Oncogene 1998; 16: 1113-1123.
66. Llond AC. Limits to lifespan. Nat Cell Biol 2002; 4: E25-E27.
67. Satyanarayana A, Wiemann SU, Buer J, et al. Telomere shortening impairs organ regeneration by inhibiting cell cycle re-entry of a subpopulation of cells. EMBO J 2003; 22: 4003-4013.
68. Schmitt CA, Fridman JS, Yang M, et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002; 109: 335-346.
69. Dimri GP, Lee X, Basile G, et al. A novel biomarker identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 1995; 92: 9363-9367.
70. Kuju KS, Lehman JM. Increased p53 protein associated with aging in human diploid fibroblasts. Exp Cell Res 1995; 217: 336-345.
71. Dirac AM, Bernards R. Reversal of senescence in mouse fibroblasts through lentiviral suppression of p53. J Biol Chem 2003; 278: 11731-11734.
72. Castro ME, del Valle Guijarro M, Moneo V, Carnero A. Cellular senescence induced by p-53-ras cooperation is independent of p21waf1 in murine embryo fibroblasts. J Cell Biochem 2004; 92: 514-524.
73. Favetta LA, Robert C, King WA, Betts DH. Expression profiles of p53 and p66shc during oxidative stress-induced senescence in fetal bovine fibroblasts. Exp Cell Res 2004; 299: 36-48.
74. 2 response of normal human fibroblasts. Biochem J 2000; 347: 543-551.
75. 2: Senescence-like growth arrest or apoptosis? Cell Growth Differ 1997; 8: 589-598.
76. Rincheval V, Renaud F, Lemaire C, et al. Bcl-2 can promote p-53 dependent senescence versus apoptosis without affecting the G1/S transition. Biochem Biophy Res Commun 2002; 298: 282-288.
77. Rebbaa A, Zheng X, Chou PM, Mirkin BL. Caspase inhibition switches doxorubicin-induced apoptosis to senescence. Oncogene 2003; 22: 2805-2811.
78. Zhang J, Patel JM, Block ER. Enhanced apoptosis in prolonged cultures of senescent porcine pulmonary artery endothelail cells. Mech Ageing dev 2002; 123: 613-625.
79. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007; 8: 275-283.
80. Campisi J, Kim SH, Lim CS, Rubio M. Cellular senescence, cencer and aging: the telomere connection. Exp Gerontol 2001; 36: 1619-1637.
81. Blackburn EH. Telomeres and telomerase: Their mechanism of action of action and the effects of altering their function. FEBS Lett 2005; 579: 859-862.
82. Cech TR. Beginning to understand the end of the chromosome. Cell 2004; 116: 273-279.
83. Blackburn EH. Switching and signaling at the telomere. Cell 2001; 106: 661-673.
84. Karlseder J, Smogorzewska A, de Lange T. Senescence induced by altered telomere state, not telomere loss. Science 2002; 295: 2446-2449.
85. Li C-Z, Eller MS, Firoozabadi R, Gilchrest BA. Evidence that exposure of the telomere 3′ overhang sequence induces senescence. Proc Natl Acad Sci USA 2003; 100: 527-531.
86. Bodnar AG, Quellete M, Frolkis M, et al. Extension of life-span by introduction of telomerase into normal human cell. Science 1998; 279; 349-352.
87. Vaziri H, Benchimol S. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr Biol 1998; 8: 279-282.
88. Zhu J, Wang H, Bishop JM, Blackburn EH. Telomerase extends the lifespan of virus-trasnformed human cells without net telomere lengthening. Proc Natl Acad Sci USA 1999; 96: 3723-3728.
89. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of huma telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-2015.
90. Morrison SJ, Prowse KR, Ho P, Weissman IL. Telomerase activity in hematopoietic cells is associated with self-renewal potential. Immunity 1996; 5: 207-216.
91. Lee HW, Blasco MA, Gottlieb GJ, Horner JW 2nd, Greider CW, DePinho RA. Essential role of mouse telomerase in highly proliferative organs. Nature 1998; 392: 569-574.
92. Smith LL, Coller HA, Roberts JM. Telomerase modulates expression of growth-controlling genes and enhances cell proliferation. Nat Cell Biol 2003; 5: 474-479.
93. Minamino T, Kourembanas S. Mechanisms of telomerase induction during vascular smooth muscle cell proliferation. Circ Res 2001; 89: 237-243.
94. Minamino T, Mitsialis SA, Kourembanas S. Hypoxia extends the life span of vascular smooth muscle cells through telomerase activation. Mol Cell Biol 2001; 21: 3336-3342.
95. Hsiao R, Sharma HW, Ramakrishnan S, Keith E, Narayanan R. Telomerase activity in normal human endothelial cells. Anticancer Res 1997; 17: 827-832.
96. Yang J, Chang E, Cherry AM, et al. Human endothelial cell life extension by telomerase expression. J Biol Chem 1999; 274: 26141-26148.
97. Ivanova NB, Dimos JT, Schaniel C, Hackney JA, Moore KA, Lemischka IR. A stem cell molecular signature. Science 2002; 298: 601-604.
98. Ramalho-Santos M, Yoon S, Matsuzaki Y, Mulligan RC, Melton DA. "Stemness" transcriptional profiling of embrypnic and adult stem cells. Science 2002; 298: 597-600.
99. Blokhina O, Virolainen E, Fagerstedt KV. Antioxidants, oxidative damage and oxygen deprivation stress: a review. Ann Bot (Lond) 2003; 91: 179-194.
100. Galasso G, Schickofer K, Sato K, et al. Impaired angiogenesis in glutathione peroxidase-1-deficient mice is associated with endothelial progenitor cell dysfunction. Circ Res 2006; 98: 254-261.
101. Forgione MA, Cap A, Liao R, et al. Heterozygous cellular glutathione peroxidase deficiency in the mouse: abnormialities in vascular and cellular function and structure. Circulation 2002; 106: 1154-1158.
102. Aicher A, Heeschen C, Midner-Rihm C, et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 2003; 9: 1370-1376.
103. Laufs U, Wemer N, Link A, et al. Physical training increases endothelial progenitor cells, inhibits neointimal formation, and enhances angiogenesis. Circulation 2004; 109: 220-226.
104. Linke A, Adams V, Schulze PC, et al. Antioxidative effects of exercise training in patients with chronic heart failure: increase in radical scavenger enzyme activity in skeletal muscle. Circulation 2005; 111: 1763-1770.
105. Colak E, Majkic-Singh N, Stankovie S, et al. Parameters of antioxidative defense in type 2 diabetes patients with cardiovascular complications. Ann Med 2005; 37: 613-620.
106. + and endothelial progenitor cells in patients with various degrees of congestive heart failure. Circulation 2004; 110: 1209-1212.
107. Scheubel RJ, Zorn H, Silber RE, et al. Age-dependent depression in circulating endothelial progenitor cells in patients undergoing coronary artery bypass grafting. J Am Coll Cardiol 2003; 42: 2073-2080.
108. Heiss C, Keymel S, Niesler U, Ziemann J, Kelm M, Kalka C. Impaired progenitor cell activity in age-related endothelial dysfunction. J Am Coll Cardiol 2005; 45: 1441-1448.
109. Loomans CJM, deKoening EJP, Staal FJT, et al. Endothelial progenitor cell dysfunction. A novel concept in the pathogenesis of vascular complications of type I diabetes. Diabetes 2004; 53: 195-199.
110. Kuki S, Imanishi T, Kobayashi K, Matsuo Y, Obana M, Akasaka T. Hyperglycemia accelerated endothelial progenitor cell senescence via an activation of p38 mitogen-activated protein kinase. Circ J 2006; 70: 1076-1081.
111. Seeger FH, Haendeler J, Walter DH, et al. p38 mitogen-activated protein kinase downregulates endothelial progenitor cells. Circulation 2005; 111: 1184-1191.
112. Adams RH, Porras A, Alonso G, et al. Essential role of p38 MAP kinase in placental but not embryonic cardiovascular development. Mol Cell 2000; 6: 106-116.
113. Matsumoto T, Turesson I, Bock M, Gerwins P, Claesson-Welsh L. p38 MAP kinase negatively regulates endothelial cell survaival, proliferation, and differentiation in FGF-2 stmulated angiogenesis. J Cell Biol 2002; 156: 149-160.
114. Gratton JP, Morales-Ruiz M, Kureishi Y, Fulton D, Walsh K, Sessa WC. Akt down-regulation of p38 signaling provides a novel mechanism of vascular endothelial growth factor-mediated cytoprotection in endothelial cells. J Biol Chem 2001; 276: 30359-30365.
115. Sorrentino SA, Bahlmann FH, Besler C, et al. Oxidant stress in vivo reendotheliazation capacity of endothelial progenitor cells from patients with type 2 diabeted mellitus. Resoration by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone. Circulation 2007; 116: 163-173.
116. Gensch C, Clever YP, Werner C, et al. The PPAR-gamma agonist pioglitazone increases neoangiogenesis and prevents apoptosis of endothelial progenitor cells. Atherosclerosis 2007; 192: 67-74.
117. Imanishi T, Kobayashi K, Kuroi A, et al. Pioglitazone inhibits angiotensin II-induced senescence of endothelial progenitor cell. Hypertens Res (in press).
118. Edelberg JM, Tang L, Hattori K, Lyden D, Rafii S. Young adult bone marrow-derived endothelial progenitor cells resotre aging-improved cardiac angiogenic function. Circ Res 2002; 90: e89-e93.
119. Scheubel RJ, Zorn H, Rolf-Edgar S, et al. Age-dependent depression in circulating endothelial progenitor cells in patients undergoing croronary artery bypass grafting. J Am Coll Cardiol 2003; 42: 2073-2080.
120. Aicher A, Heeschen C, Mildner-Rihm C, et al. Essential role of endothelial nitric oxide synthase for mobilization of stem cell and progenitor cells. Nat Med 2003; 9: 1370-1376.
121. Matsushita H, Chang E, Glassford AJ, Cooke JP, Chiu CP, Tsao PS. eNOS activity is reduced in senescent human endothelial cells: preservation by hTERT immortalization. Circ Res 2001; 89: 793-798.
122. Bernardini D, Ballabio E, Mariotti M, Maiser JA. Differential expression of EDF-1 and endothelial nitric oxide synthase by proliferating, quiescent and senescent microvascular endothelial cells. Biochem Biophys Acta 2005; 1745: 265-272.
123. Iwakura A, Luedemann C, Shastry S, et al. Estrogen-mediated, endothelial nitric oxide synthase-dependent mobilization of bone marrow-derived endothelial progenitor cells contributes to reendotheliazation after arterial injury. Circulation 2003; 108: 3115-3121.
124. Papapetropoulos A, Gracia-Cardena G, Madri JA, Sessa WC. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endohtleial cells. J Clin Invest 1997; 100: 3131-3139.
125. Lantin-Hermoso RL, Rosenfeld CR, Yuhanna IS, German Z, Chen Z, Shaul PW. Estrogen acutely stimulates nitric oxide synthase activity in fetal pulmonary artery endothelium. Am J Physiol 1997; 273: L119-L126.
126. Ma FX, Zhou B, Chen Z, et al. Oxidized low density lipoprotein impairs endothelial progenitor cells by regulation of endothelial nitric oxide synthase. J Lipid Res 2006; 47: 1227-1237.
127. Imanishi T, Hano T, Sawamura T, Nishio I. Oxidized low-density lipoprotein induces endothelial progenitor cell senescence, leading to cellular dysfunction. Clin Exp Pharmacol Physiol 2004; 31: 407-413.
128. Imanishi T, Hano T, Matsuo Y, Nishio I. Oxidized low-density lipoprotein inhibits vascular endothelial growth factor-induced endothelial progenitor cell differentiation. Clin Exp Pharmacol Physiol 2003; 30: 665-670.
129. Dimmeler S, Aisher A, Vasa M, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells viathe PI3-kinase/ Akt pathway. J Clin Invest 2001; 108: 391-397.
130. Breitschopf K, Zeiher AM, Dimmeler S. Pro-atherogenic factors induce telomerase inactivation in endothelial cells through an Akt-dependent mechanism. FEBS Lett 2001; 493: 21-25.
131. Touyz RM. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance? Hypertension 2004; 44: 248-252.
132. Sowers JR. Hypertension, Angiotensin II, and Oxidative Stress. N Engl J Med 2002; 346: 1999-2001.
133. Lassegue B, Clempus RE. Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am J Physiol 2003; 285: R277-R297.
134. Imanishi T, Moriwaki C, Hano T, et al. Endothelial progenitor cell senescence is accelerated in both experimental hypertensive rats and patients with hypertension. J Hypertens 2005; 23: 1831-1837.
135. Fadini GP, Coracina A, Baesso I, et al. Peripheral blood CD34+KDR+ endothelial progenitor cells are determinants of subclinical atherosclerosis in a middle-aged general population. Stroke 2006; 37: 2277-2282.
136. Bahlmann FH, de Groot K, Mueller OH, Hertel B, Haller H, Fliser D. Stimulation of endothelial progenitor cells-a new putative therapeutic effect of angiotensin II receptor antagonism. Hypertension 2005; 45: 526-529.
137. Min TQ, Zhu CJ, Xiang WX, Hui ZJ, Peng SY. Improvement in endothelial progenitor cells from peripheral blood by ramipril therapy in patients with stable coronary artery disease. Cardiovasc Drugs Ther 2004; 18: 203-209.
138. Imanishi T, Hano T, Nishio I. Angiotensin II accelerates endothelial progenitor cell senescence through induction of oxidative stress. J Hypertens 2005; 23: 97-104.
139. Heitzer T, Wenzel U, Hink U, et al. Increased NAD(P)H oxidase-mediated superoxide production in renovascular hypertension: evidence for an involvement of protein kinase C. Kidney Int 1999; 55: 252-260.
140. Rodgers KE, Xiong S, Steer R, diZerega GS. Effect of angiotensin II on hematopoietic progenitor cell proliferation. Stem Cells 2000; 18: 287-294.
141. Sasaki K, Murohara T, Ikeda H, et al. Evidence for the importance of angiotensin II type 1 receptor in ischemia-induced angiogenesis. J Clin Invest 2002; 109: 603-611.
142. Egami K, Murohara T, Shimada T, et al. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest 2003; 112: 67-75.
143. Noble M, Smith J, Power J, Mayer-Proschel M. Redox state as a central modulator of precursor cell function. Ann NY Acad Sci 2003; 991: 251-271.
144. Walter DH, Rittig K, Bahlmann FH, et al. Statin therapy accelerates reendotheliazation: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 2002; 105: 3017-3024.
145. Werner N, Priller J, Laufs U, et al. Bone marrow-derived progenitor cells modulate vascular reendotheliazation and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. Arterioscler Thromb Vasc Biol 2002; 22: 1567-1572.
146. Llevadot J, Murasawa S, Kureishi Y, et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest 2001; 108: 399-405.
147. Spyridopoulos I, Haendeler J, Urbich C, et al. Statins enhance migratory capacity by upregulation of the telomere repeat-binding factor TRF2 in endothelial progenitor cells. Circulation 2004; 110: 3136-3142.
148. Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000; 6: 1004-1010.
149. Gerber HP, McMurtrey A, Kowalski J, et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998; 273: 30336-30343.
150. Assmus B, Schachinger V, Teupe C, et al. Transplatation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation 2002; 106: 3009-3017.
151. Rueckschloss U, Quinn MT, Holtz J, Morawietz H. Dosedependent regulation of NAD(P)H oxidase expression by angiotensin II in human endothelial cells: Protective effect of angiotensin II type 1 receptor blockade in patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2002; 22: 1845-1851.
152. Yao EH, Fukuda N, Matsumoto T, et al. Losartan improves the impaired function of endothelial progenitor cells in hypertension via an antioxidant effect. Hypertens Res 2007; 30: 1119-1128.
153. Imanishi T, Kobayashi K, Hano T, Nishio I. Effect of estrogen on differentiation and senescence in endothelial progenitor cells derived from bone marrow in spontaneously hypertensive rats. Hypertens Res 2005; 28: 763-772.
154. Imanishi T, Hano T, Nishio I. Estrogen reduces endothelial progenitor cell senescence through augmentation of telomerase activity. J Hypertens 2005; 23: 1699-1706.
155. Masutomi K, Yu EY, Khurts S, Ben-Porath I, Currier JL, Metz GB, Brooks MW, Kaneko S, Murakami S, DeCaprio JA, Weinberg RA, Stewart SA, Hahn WC. Telomerase maintains telomere structure in normal human cells. Cell 2003; 114: 241-253.
156. Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, Knopp R, Lowery M, Satterfield S, Schrott H, Vittinghoff E, Hunninghake D; HERS Research Group. JAMA 2002; 288: 58-66.